Search research articles
Contact Us
Filters
Showing results (181-190 of 274) with videos related to
Page
of 28
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2021
A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia
Gang An, Daobin Zhou, Shu Cheng, et al.
Oncotarget
|
March 21, 2016
Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis
Mu Hao, Meirong Zang, Lei Zhao, et al.
Blood Science (Baltimore, Md.)
|
June 4, 2024
Subcutaneous daratumumab in Chinese patients with relapsed or refractory multiple myeloma: an open-label, multicenter, phase 1 study (MMY1010)
Gang An, Zheng Ge, Hongmei Jing, et al.
Annals of Hematology
|
December 4, 2023
Immunophenotypic profile defines cytogenetic stability and unveils distinct prognoses in patients with newly-diagnosed multiple myeloma (NDMM)
Lihui Shi, Wenqiang Yan, Jingyu Xu, et al.
Hematology (Amsterdam, Netherlands)
|
September 19, 2023
The age-dependent changes in risk weights of the prognostic factors for multiple myeloma
Chenxing Du, Lingna Li, Huishou Fan, et al.
Forensic Science International. Genetics
|
November 26, 2018
Genotyping polymorphic microhaplotype markers through the Illumina<sup>®</sup> MiSeq platform for forensics
Jing Zhu, Meili Lv, Nan Zhou, et al.
British Journal of Haematology
|
July 30, 2021
Undetectable minimal residual disease is an independent prognostic factor in splenic marginal zone lymphoma
Rui Lyu, Tingyu Wang, Yi Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 7, 2025
Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Wenjie Xiong, Yuting Yan, Tingyu Wang, et al.
Cancer Medicine
|
February 13, 2024
Gemcitabine-based conditioning compared to BEAM/BEAC conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: No difference in outcomes
Huimin Liu, Hesong Zou, Dandan Shan, et al.
Haematologica
|
August 3, 2023
Minor clone of del(17p) provides a reservoir for relapse in multiple myeloma
Jian Cui, Rui Lv, Tengteng Yu, et al.
Page
of 28
Search research articles
Search
Showing results (181-190 of 274) with videos related to
Sort By:
Page
of 28
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2021
A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia
Gang An, Daobin Zhou, Shu Cheng, et al.
Oncotarget
|
March 21, 2016
Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis
Mu Hao, Meirong Zang, Lei Zhao, et al.
Blood Science (Baltimore, Md.)
|
June 4, 2024
Subcutaneous daratumumab in Chinese patients with relapsed or refractory multiple myeloma: an open-label, multicenter, phase 1 study (MMY1010)
Gang An, Zheng Ge, Hongmei Jing, et al.
Annals of Hematology
|
December 4, 2023
Immunophenotypic profile defines cytogenetic stability and unveils distinct prognoses in patients with newly-diagnosed multiple myeloma (NDMM)
Lihui Shi, Wenqiang Yan, Jingyu Xu, et al.
Hematology (Amsterdam, Netherlands)
|
September 19, 2023
The age-dependent changes in risk weights of the prognostic factors for multiple myeloma
Chenxing Du, Lingna Li, Huishou Fan, et al.
Forensic Science International. Genetics
|
November 26, 2018
Genotyping polymorphic microhaplotype markers through the Illumina<sup>®</sup> MiSeq platform for forensics
Jing Zhu, Meili Lv, Nan Zhou, et al.
British Journal of Haematology
|
July 30, 2021
Undetectable minimal residual disease is an independent prognostic factor in splenic marginal zone lymphoma
Rui Lyu, Tingyu Wang, Yi Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 7, 2025
Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Wenjie Xiong, Yuting Yan, Tingyu Wang, et al.
Cancer Medicine
|
February 13, 2024
Gemcitabine-based conditioning compared to BEAM/BEAC conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: No difference in outcomes
Huimin Liu, Hesong Zou, Dandan Shan, et al.
Haematologica
|
August 3, 2023
Minor clone of del(17p) provides a reservoir for relapse in multiple myeloma
Jian Cui, Rui Lv, Tengteng Yu, et al.
Page
of 28